Recent News

• 08.03.2026 - Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
• 08.03.2026 - Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
• 07.13.2026 - Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
• 07.10.2026 - Cue Biopharma Announces $50.0 Million Private Placement
• 06.10.2026 - Daniel Baker, M.D.
• 06.10.2026 - Daniel Baker, M.D.
• 06.10.2026 - Sumita Ray, J.D.
• 06.10.2026 - Sumita Ray, J.D.
• 06.02.2026 - Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
• 06.02.2026 - Viola Meehan

Recent Filings

• 08.03.2026 - 8-K Current report
• 08.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.03.2026 - 3 Initial statement of beneficial ownership of securities
• 07.30.2026 - 4/A Statement of changes in beneficial ownership of securities
• 07.22.2026 - D Notice of Exempt Offering of Securities
• 07.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.15.2026 - 3 Initial statement of beneficial ownership of securities
• 07.10.2026 - 8-K Current report
• 07.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.10.2026 - 4 Statement of changes in beneficial ownership of securities